Download PDFPDF

Severe paediatric pulmonary hypertension: new management strategies
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Adenosine Infusion for the managment of persistent pulmonary hypertension of the newborn

    Dear Editor,

    I would like to take this opportunity to inform the readers about recent developments in the drug management of pulmonary hypertension since my review was originally submitted.

    Workers at Great Ormond Street have shown that the intravenous administration of adenosine in combination with inhaled nitric oxide may be useful in neonates with pulmonary hypertension of the newborn [1]. It causes...

    Show More
    Conflict of Interest:
    None declared.